Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70182 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Koji Fujita und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Organoplatinum Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, with a rising incidence. The most common therapeutic choice for HCC is transarterial chemoembolization (TACE). While the standard protocol of TACE adopts cisplatin, the application of cisplatin needs hydration before and after the procedure to alleviate adverse effects on kidney function. Miriplatin, a lipophilic platinum complex, enables the omission of periprocedural hydration compared to cisplatin‐based TACE. This study aimed to compare the survival benefit between miriplatin‐based TACE and cisplatin‐based TACE. Briefly, a retrospective cohort study in a single hospital was designed. Patients with HCC complicated by vascular invasion or distant metastasis were excluded. Background variability was adjusted using a propensity score matching; then, overall survival rates were compared using the Gehan‐Breslow‐Wilcoxon test. As a result, cisplatin and miriplatin were administered to 166 and 120 patients in TACE procedures. After adjusting baseline characteristics using a propensity score including age, sex, tumor burden, functional hepatic reserve, baseline year, and HbA1c, a pair of 99‐patient cohorts was generated. Overall survivals did not differ significantly, despite poorer serum creatinine at baseline (0.89 vs. 0.74 mg/dL, p < 0.0001) and fewer patients being prepared for TACE through prehydration (18 patients vs. 38 ones, p = 0.0025) in the miriplatin group than in the cisplatin group. The median survival time was 1490 days for the miriplatin group and 1,830 days for the cisplatin group ( p = 0.4022; ratio = 0.814; 95% confidence interval 0.546–1.215). In conclusion, miriplatin will benefit patients with HCC who cannot tolerate perioperative hydration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
- Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Japan.
ORCID-Profile: Koji Fujita
Zitieren
APA
Fujita, K., Takuma, K., Oura, K., Tadokoro, T., Morishita, A., Himoto, T., & Kobara, H. (2025). Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration. Clinical and Translational Science. https://doi.org/10.1111/cts.70182
Vancouver
Fujita K, Takuma K, Oura K, Tadokoro T, Morishita A, Himoto T, et al. Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration. Clinical and Translational Science. 2025. doi:10.1111/cts.70182
BibTeX
@article{Fujita2025,
author = {Fujita, Koji and Takuma, Kei and Oura, Kyoko and Tadokoro, Tomoko and Morishita, Asahiro and Himoto, Takashi and Kobara, Hideki},
title = {Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70182}
}
EUVIMED